Effectiveness of mobile smoking cessation treatment with 1-week nicotine replacement therapy sampling at outdoor smoking hotspots: A cluster randomized controlled trial.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Two-arm cluster RCT (1:1 ratio), single-blinded, at 244 recruitment sessions in Hong Kong outdoor smoking hotspots from October 2018-December 2019.

Participant were recruited by ambassadors and treated at the mobile SC truck.

How the Study Was Run

The researchers set it up as a randomized and single-blind study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

In this single-blind Therapeutic nicotine (patch, non-peptide) study one party knew the assignments and the other did not.

The experimental group received a 1-week free NRT sample, an NRT instruction card, and mobile SC treatment including onsite nurse-led brief medication advice (about 15 minutes) and referral to SC clinics.

The control group received the same mobile SC treatment.

Primary outcome was self-reported quit attempts at 1-month follow-up.

Secondary outcomes included SC service use at 1 month, and biochemically validated abstinence (exhaled carbon monoxide < 4 ppm; or saliva cotinine < 10 ng/ml) at 6-month follow-up.

Additionally, a post-hoc cost analysis was conducted.

What Was Measured

Topics PubMed links to this paper include Smoking Cessation, Hong Kong, Tobacco Use Cessation Devices and Nicotine Replacement Therapy.

Author keywords: 1‐week nicotine replacement therapy sampling, cessation service use at clinics, clinical trial, community smoker, mobile truck and process outcome.

What This Means in Plain Language

The paper is a randomized and single-blind study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Addiction (Abingdon, England)), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.